Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis

Sara Bringhen, Massimo Offidani, Salvatore Palmieri, Francesco Pisani, Rita Rizzi, Stefano Spada, Andrea Evangelista, Nicola Di Renzo, Pellegrino Musto, Magda Marcatti, Roberto Vallone, Sergio Storti, Annalisa Bernardini, Riccardo Centurioni, Enrico Aitini, Angelo Palmas, Ombretta Annibali, Emanuele Angelucci, Paola Ferrando, Anna BaraldiStefano Rocco, Alessandro Andriani, Agostina Siniscalchi, Valerio De Stefano, Vittorio Meneghini, Antonio Palumbo, Sara Grammatico, Mario Boccadoro, Alessandra Larocca

Research output: Contribution to journalArticle

Abstract

Introduction: Early toxic death (≤60 days of diagnosis) in elderly multiple myeloma (MM) patients is attributable to active disease, age and co-morbidities. Rate of early toxic deaths is 10% with conventional chemotherapy mainly due to infection and renal failure. Novel agents have improved MM outcome at the expense of newer toxicity. Methods: We analyzed 1146 individual patient data to assess toxic deaths during induction treatment with first-generation novel agents thalidomide, lenalidomide, bortezomib. Results: During first-line therapy, 119/1146 patients (10%) died for any cause, and 47/1146 (4%) due to toxicity, including 12/1146 (1%) early deaths. The 24-month cumulative incidence was 4.1% without any difference between bortezomib (18/503 patients, 4%) and lenalidomide (29/643patients, 5%; p = 0.31). Toxic deaths occurred in 34/1039 (3%) patients
Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume130
DOIs
Publication statusPublished - Oct 1 2018

Cite this

Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis. / Bringhen, Sara; Offidani, Massimo; Palmieri, Salvatore; Pisani, Francesco; Rizzi, Rita; Spada, Stefano; Evangelista, Andrea; Di Renzo, Nicola; Musto, Pellegrino; Marcatti, Magda; Vallone, Roberto; Storti, Sergio; Bernardini, Annalisa; Centurioni, Riccardo; Aitini, Enrico; Palmas, Angelo; Annibali, Ombretta; Angelucci, Emanuele; Ferrando, Paola; Baraldi, Anna; Rocco, Stefano; Andriani, Alessandro; Siniscalchi, Agostina; De Stefano, Valerio; Meneghini, Vittorio; Palumbo, Antonio; Grammatico, Sara; Boccadoro, Mario; Larocca, Alessandra.

In: Critical Reviews in Oncology/Hematology, Vol. 130, 01.10.2018, p. 27-35.

Research output: Contribution to journalArticle

Bringhen, S, Offidani, M, Palmieri, S, Pisani, F, Rizzi, R, Spada, S, Evangelista, A, Di Renzo, N, Musto, P, Marcatti, M, Vallone, R, Storti, S, Bernardini, A, Centurioni, R, Aitini, E, Palmas, A, Annibali, O, Angelucci, E, Ferrando, P, Baraldi, A, Rocco, S, Andriani, A, Siniscalchi, A, De Stefano, V, Meneghini, V, Palumbo, A, Grammatico, S, Boccadoro, M & Larocca, A 2018, 'Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis', Critical Reviews in Oncology/Hematology, vol. 130, pp. 27-35. https://doi.org/10.1016/j.critrevonc.2018.07.003
Bringhen, Sara ; Offidani, Massimo ; Palmieri, Salvatore ; Pisani, Francesco ; Rizzi, Rita ; Spada, Stefano ; Evangelista, Andrea ; Di Renzo, Nicola ; Musto, Pellegrino ; Marcatti, Magda ; Vallone, Roberto ; Storti, Sergio ; Bernardini, Annalisa ; Centurioni, Riccardo ; Aitini, Enrico ; Palmas, Angelo ; Annibali, Ombretta ; Angelucci, Emanuele ; Ferrando, Paola ; Baraldi, Anna ; Rocco, Stefano ; Andriani, Alessandro ; Siniscalchi, Agostina ; De Stefano, Valerio ; Meneghini, Vittorio ; Palumbo, Antonio ; Grammatico, Sara ; Boccadoro, Mario ; Larocca, Alessandra. / Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis. In: Critical Reviews in Oncology/Hematology. 2018 ; Vol. 130. pp. 27-35.
@article{1903b9b7aa1242e284e8d413a4ba9c2f,
title = "Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis",
abstract = "Introduction: Early toxic death (≤60 days of diagnosis) in elderly multiple myeloma (MM) patients is attributable to active disease, age and co-morbidities. Rate of early toxic deaths is 10{\%} with conventional chemotherapy mainly due to infection and renal failure. Novel agents have improved MM outcome at the expense of newer toxicity. Methods: We analyzed 1146 individual patient data to assess toxic deaths during induction treatment with first-generation novel agents thalidomide, lenalidomide, bortezomib. Results: During first-line therapy, 119/1146 patients (10{\%}) died for any cause, and 47/1146 (4{\%}) due to toxicity, including 12/1146 (1{\%}) early deaths. The 24-month cumulative incidence was 4.1{\%} without any difference between bortezomib (18/503 patients, 4{\%}) and lenalidomide (29/643patients, 5{\%}; p = 0.31). Toxic deaths occurred in 34/1039 (3{\%}) patients",
keywords = "Bortezomib, Early mortality, Lenalidomide, Multiple myeloma, New drugs, Newly diagnosed, Thalidomide, Toxic death, Transplant-Ineligible",
author = "Sara Bringhen and Massimo Offidani and Salvatore Palmieri and Francesco Pisani and Rita Rizzi and Stefano Spada and Andrea Evangelista and {Di Renzo}, Nicola and Pellegrino Musto and Magda Marcatti and Roberto Vallone and Sergio Storti and Annalisa Bernardini and Riccardo Centurioni and Enrico Aitini and Angelo Palmas and Ombretta Annibali and Emanuele Angelucci and Paola Ferrando and Anna Baraldi and Stefano Rocco and Alessandro Andriani and Agostina Siniscalchi and {De Stefano}, Valerio and Vittorio Meneghini and Antonio Palumbo and Sara Grammatico and Mario Boccadoro and Alessandra Larocca",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.critrevonc.2018.07.003",
language = "English",
volume = "130",
pages = "27--35",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis

AU - Bringhen, Sara

AU - Offidani, Massimo

AU - Palmieri, Salvatore

AU - Pisani, Francesco

AU - Rizzi, Rita

AU - Spada, Stefano

AU - Evangelista, Andrea

AU - Di Renzo, Nicola

AU - Musto, Pellegrino

AU - Marcatti, Magda

AU - Vallone, Roberto

AU - Storti, Sergio

AU - Bernardini, Annalisa

AU - Centurioni, Riccardo

AU - Aitini, Enrico

AU - Palmas, Angelo

AU - Annibali, Ombretta

AU - Angelucci, Emanuele

AU - Ferrando, Paola

AU - Baraldi, Anna

AU - Rocco, Stefano

AU - Andriani, Alessandro

AU - Siniscalchi, Agostina

AU - De Stefano, Valerio

AU - Meneghini, Vittorio

AU - Palumbo, Antonio

AU - Grammatico, Sara

AU - Boccadoro, Mario

AU - Larocca, Alessandra

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Introduction: Early toxic death (≤60 days of diagnosis) in elderly multiple myeloma (MM) patients is attributable to active disease, age and co-morbidities. Rate of early toxic deaths is 10% with conventional chemotherapy mainly due to infection and renal failure. Novel agents have improved MM outcome at the expense of newer toxicity. Methods: We analyzed 1146 individual patient data to assess toxic deaths during induction treatment with first-generation novel agents thalidomide, lenalidomide, bortezomib. Results: During first-line therapy, 119/1146 patients (10%) died for any cause, and 47/1146 (4%) due to toxicity, including 12/1146 (1%) early deaths. The 24-month cumulative incidence was 4.1% without any difference between bortezomib (18/503 patients, 4%) and lenalidomide (29/643patients, 5%; p = 0.31). Toxic deaths occurred in 34/1039 (3%) patients

AB - Introduction: Early toxic death (≤60 days of diagnosis) in elderly multiple myeloma (MM) patients is attributable to active disease, age and co-morbidities. Rate of early toxic deaths is 10% with conventional chemotherapy mainly due to infection and renal failure. Novel agents have improved MM outcome at the expense of newer toxicity. Methods: We analyzed 1146 individual patient data to assess toxic deaths during induction treatment with first-generation novel agents thalidomide, lenalidomide, bortezomib. Results: During first-line therapy, 119/1146 patients (10%) died for any cause, and 47/1146 (4%) due to toxicity, including 12/1146 (1%) early deaths. The 24-month cumulative incidence was 4.1% without any difference between bortezomib (18/503 patients, 4%) and lenalidomide (29/643patients, 5%; p = 0.31). Toxic deaths occurred in 34/1039 (3%) patients

KW - Bortezomib

KW - Early mortality

KW - Lenalidomide

KW - Multiple myeloma

KW - New drugs

KW - Newly diagnosed

KW - Thalidomide

KW - Toxic death

KW - Transplant-Ineligible

U2 - 10.1016/j.critrevonc.2018.07.003

DO - 10.1016/j.critrevonc.2018.07.003

M3 - Article

VL - 130

SP - 27

EP - 35

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -